Summary
Amgen Inc. (AMGN) has filed an 8-K to disclose that the U.S. Federal Trade Commission (FTC) has filed a complaint seeking to block Amgen's proposed acquisition of Horizon Therapeutics plc. The FTC's action was initiated in the United States District Court for the Northern District of Illinois on May 16, 2023, aiming to prevent the completion of the acquisition. In response to the FTC's lawsuit, Amgen issued a press release on the same date, the content of which is included as an exhibit to this filing. Investors should closely monitor the legal proceedings and any further updates from Amgen or the FTC regarding this significant transaction, as the outcome will have a material impact on Amgen's future growth and strategic direction.
Key Highlights
- 1FTC files lawsuit to block Amgen's acquisition of Horizon Therapeutics.
- 2The complaint was filed in the U.S. District Court for the Northern District of Illinois.
- 3Amgen issued a press release in response to the FTC's action on May 16, 2023.
- 4The acquisition was originally announced on December 11, 2022.
- 5This filing serves as a Regulation FD disclosure regarding the FTC's legal action.
Frequently Asked Questions
This 8-K filing is primarily to inform investors that the U.S. Federal Trade Commission (FTC) has filed a lawsuit seeking to prevent Amgen's acquisition of Horizon Therapeutics.
Amgen issued a press release on May 16, 2023, in response to the FTC's action. The details of their response are available in Exhibit 99.1 of this filing.
The FTC's lawsuit creates significant uncertainty regarding the completion of the acquisition. The outcome of this legal challenge will determine whether Amgen can proceed with acquiring Horizon Therapeutics.
More information can be found in the press release attached as Exhibit 99.1 to this 8-K filing.